DESSOLVE III is a prospective, randomized, balanced, controlled, single-blind, multi-center study comparing clinical outcomes at 12 months between MiStent and Xience® in a real world, all-comers patient population (patients with symptomatic coronary artery disease including patients with chronic stable angina, silent ischemia, and acute coronary syndromes, who qualify for percutaneous coronary interventions). Enrollment included more than 1,400 patients randomized to MiStent SES or Xience at 20 sites in Europe.
The primary endpoint for this trial is a non-inferiority comparison of a device-oriented composite endpoint (DOCE) or TLF of the MiStent SES group to the Xience group at 12 months post-procedure. TLF is a composite of cardiac death, myocardial infarction (MI) not clearly attributable to a non-target vessel and clinically indicated TLR.
Patrick Serruys, M.D., Ph.D., International Center for Circulatory Health, NHLI, Imperial College, London, UK
William Wijns, M.D., Ph.D., Cardiovascular Center, Aalst, Belgium
Robbert de Winter, M.D., Ph.D, Academisch Medisch Centrum, Amsterdam, The Netherlands
More information on the DESSOLVE III trial can be found here.